Skip to content
★ Sign in to follow
Wuhan YZY Biopharma Co., Ltd. - B logo

Wuhan YZY Biopharma Co., Ltd. - B Stock: price and insider trades · Hong Kong

HK·Mcap HK$523.4MHealth Care

No insider purchase over the last 90 days. The latest, by WEN Zhicheng, was filed 01 Apr 2026.

Wuhan YZY Biopharma Co., Ltd. - B: what insiders have been doing

Wuhan YZY Biopharma Co., Ltd. - B is a Health Care company. Its directors and officers file their transactions with HKEX. In the past year (31 October 2025 to 31 October 2026), 8 filings came from 4 insiders.

The record shows 4 purchases on the open market, made by 4 insiders, against 4 sales by 4 insiders. The totals do not cover 8 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.

The clock since the last published purchase (1 April 2026) now reads 221 days. The median gap between a trade and its publication by HKEX is 2 days. That lag is the time during which only the insider knows about the trade.

With 8 filings in twelve months, the company is more active than the median of 4 filings across the 1,323 companies we follow on the same exchange. Looking back to 2026, when coverage begins, insiders filed 4 purchases and 4 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. This summary is built from HKEX disclosures alone and does not predict where the share price will go.

Insider Decl.
8
Thresholds
n/a
Buy Volume
n/a
4 ops. · all time
Sell Volume
n/a
4 ops. · all time

Who traded when

BuySale
WEN Zhicheng1 buy1 sale
Yuan Qian1 buy1 sale
Zhou Hongfeng1 buy1 sale
Zhou Pengfei1 buy1 sale

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$2.70
Analyst consensus
·
Income statement
RevenueHK$66.9M
Gross profitHK$10.7M16% margin
EBITDA-HK$75.3M-113% margin
Net income-HK$84.7M-55.2% margin
Valuation
Beta0.48
Balance sheet & cash
Market capHK$523.4M
Total debtHK$127.8M
Free Cash Flow-HK$22.5M
Profitability & ownership
ROA-7.9%
% insiders73.4%
% institutions17.8%
Last declaration on 1 April 2026
Declarations8 total
  • ▲
    Executives
    0HKEX
    5,059,039 sharesShareXHKGHKEX:DA20260331E00384
    Canonical exit: 28 Jun 2026 (T+90)
  • ▼
    Executives
    0HKEX
    5,059,039 sharesShareXHKGHKEX:DA20260331E00383
  • ▼
    Executives
    0HKEX
    54,262,305 sharesShareXHKGHKEX:DA20260331E00375
  • ▼
    Executives
    0HKEX
    54,262,305 sharesShareXHKGHKEX:DA20260331E00392
  • ▲
    Executives
    0HKEX
    54,262,305 sharesShareXHKGHKEX:DA20260331E00391
    Canonical exit: 28 Jun 2026 (T+90)
  • ▼
    Executives
    0HKEX
    54,262,305 sharesShareXHKGHKEX:DA20260331E00390
  • ▲
    Executives
    0HKEX
    54,262,305 sharesShareXHKGHKEX:DA20260331E00376
    Canonical exit: 28 Jun 2026 (T+90)
  • ▲
    Executives
    0HKEX
    54,262,305 sharesShareXHKGHKEX:DA20260331E00393
    Canonical exit: 28 Jun 2026 (T+90)

8 of 8 declarations

About Wuhan YZY Biopharma Co., Ltd. - B

Wuhan YZY Biopharma Co., Ltd. is a company focused on the health and pharmaceutical sector. It is listed on the Hong Kong Stock Exchange (XHKG).

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations